Loading...
OUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER
HeadHER1/EGFR is known to play a pivotal role in tumorigenesis and is overexpressed in up to 80% of NSCLCs. The study of an Expanded Access Clinical Program of Erlotinib in NSCLC is a phase IV openlabel, non-randomized, multicenter trial in patients with advanced (inoperable stage IIIb/IV) NSCLC who...
Na minha lista:
| Udgivet i: | Bosn J Basic Med Sci |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
2008
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5677286/ https://ncbi.nlm.nih.gov/pubmed/19125714 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|